How is CRISPR delivered to specific cells without triggering immune responses?

[Tyler54]

I was reading a popular science article about recent advances in CRISPR gene editing, and it mentioned correcting single-point mutations. The concept makes sense, but I'm confused about the delivery mechanism. How do they actually get the editing tools into the specific cells of a living organism without causing a massive immune response or editing the wrong places?

[Luna_H]

CRISPR delivery is the hard part, in practice people either use viral vectors like AAV to ferry Cas9 and guide RNA into cells or non viral carriers like lipid nanoparticles that bring Cas9 mRNA or the protein RNPs into the right cells. Each route has clear trade offs AAV is efficient and reasonably tissue friendly but has cargo limits and immune risks while non viral methods avoid long term expression but still face challenges getting enough material into the right tissues without being cleared first. CRISPR delivery is a recurring bottleneck in the field. citeturn0search8turn0search3turn0search0

[Abigail_J]

Immune issues are real many people already have antibodies to common Cas9 proteins and some carry pre existing immunity to AAV which can limit effectiveness or trigger responses. Researchers try to mitigate by using different Cas9 variants delivering only transiently (RNPs or mRNA) or by non viral delivery strategies. citeturn0search3turn0search7turn0search8

[HannahC]

SORT nanoparticles are a hot area; Nature Nanotechnology in 2020 described selective organ targeting lipid nanoparticles that can bias delivery to liver lung or spleen and have been used for CRISPR editing in specific tissues. It’s still early but points toward avoiding edits in the wrong places. citeturn1search0turn1search2

[DanielB]

To reduce off target editing researchers design guide RNAs carefully and use high fidelity Cas9 variants; the idea is to limit where and how long the nuclease is active. It’s not magical—it's risk management built into the design. citeturn0search8

[Brian36]

Ex vivo approaches (editing cells outside the body and then returning them to the patient) give extra safety controls because you can screen edits before implantation, but they’re not suitable for all tissues and diseases. citeturn0search8

[Daniel_G]

Delivery success really depends on tissue; liver editing with lipid nanoparticles has been demonstrated repeatedly in mice, while many other organs remain more challenging. That’s why in vivo CRISPR is still largely in the research and early clinical stages. citeturn0search0

[James.R]

If you’ve got a particular tissue or disease in mind, tell me and I’ll map a high level, non actionable overview of the in vivo and ex vivo options that researchers actually use today.